These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
43. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. Roukos DH J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920 [No Abstract] [Full Text] [Related]
44. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Bedard PL; Piccart-Gebhart MJ Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036 [TBL] [Abstract][Full Text] [Related]
45. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558 [TBL] [Abstract][Full Text] [Related]
46. Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer. Saji S; Sato F; Ueno NT Nat Rev Clin Oncol; 2012 Jun; 9(7):. PubMed ID: 22665363 [No Abstract] [Full Text] [Related]
47. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. Cho WC; Roukos DH Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420 [No Abstract] [Full Text] [Related]
48. Adjuvant chemotherapy for early-stage breast cancer. McArthur HL; Hudis CA Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445 [TBL] [Abstract][Full Text] [Related]
49. Optimizing the use of anthracyclines in older patients with breast cancer. Morris PG; Fornier MN Crit Rev Oncol Hematol; 2011 Feb; 77(2):131-41. PubMed ID: 20227291 [TBL] [Abstract][Full Text] [Related]
50. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662 [TBL] [Abstract][Full Text] [Related]
51. [Adjuvant chemotherapy for breast cancer: search for new ways of planning]. Semiglazov VF; Semiglazov VV; Paltuev PM; Dashian GA; Donskikh RV; Komiakhov AV; Krivorot'ko PV; Nikolaev KS; Nikitina IV; Semiglazova TIu Vopr Onkol; 2014; 60(1):102-8. PubMed ID: 24772626 [TBL] [Abstract][Full Text] [Related]
52. Adjuvant chemotherapy in luminal breast cancers. Lim E; Winer EP Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279 [TBL] [Abstract][Full Text] [Related]
53. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy. Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283 [TBL] [Abstract][Full Text] [Related]
54. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?]. MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401 [No Abstract] [Full Text] [Related]
55. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments. Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499 [TBL] [Abstract][Full Text] [Related]
56. Palbociclib: an approval at last for HER2-negative breast cancer. Zerdes I; Ziogas DE; Lykoudis EG; Roukos DH Future Oncol; 2016 May; 12(9):1097-100. PubMed ID: 26987714 [No Abstract] [Full Text] [Related]
57. Fifteen years of anti-HER2 therapy. Davidson NE Oncology (Williston Park); 2013 Mar; 27(3):151. PubMed ID: 23687781 [No Abstract] [Full Text] [Related]
58. Neratinib (Nerlynx) for HER2-positive breast cancer. Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199 [No Abstract] [Full Text] [Related]
59. A drug-delivery vehicle combining the targeting and thermal ablation of HER2+ breast-cancer cells with triggered drug release. You JO; Guo P; Auguste DT Angew Chem Int Ed Engl; 2013 Apr; 52(15):4141-6. PubMed ID: 23494862 [TBL] [Abstract][Full Text] [Related]
60. Some HER2-Negative Breast Tumors May Respond to HER2-Targeted Treatment. Rochman S J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628662 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]